TY  - CHAP
M1  - Book, Section
TI  - Immunomodulatory Drugs and Proteasome Inhibitors
A1  - Mahindra, Anuj
A1  - Mujagic, Hamza
A1  - Chabner, Bruce A.
A2  - Chabner, Bruce A.
A2  - Longo, Dan L.
PY  - 2016
T2  - Harrison's Manual of Oncology, 2e
AB  - The  therapeutic  options  for  the  treatment  of  multiple  myeloma  (MM)  have  expanded  over  the  past  decade  with  the  introduction  of  novel  biologically  targeted  agents,  which  in  turn  have  resulted  in  significantly  improved  outcomes  (1).  The  use  of  the  immunomodulatory  drug  thalidomide  in  the  1990s  and  subsequently  its  analogue  lenalidomide  and  more  recently  pomalidomide  has  been  a  major  advance  in  the  field.  The  proteasome  inhibitor,  bortezomib,  was  FDA  approved  in  2003,  and  the  next-generation  proteasome  inhibitors  are  now  undergoing  evaluation  in  clinical  trials.  Antibodies  targeting  membrane-bound  receptors  are  another  promising  class  of  agents.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - hemonc.mhmedical.com/content.aspx?aid=1127646531
ER  -